Understanding the molecular details of dioxin/Ah receptor (AHR) signal transduction will yield a number of benefits. First, identifying modifiers of AHR signaling will help explain the tissue and species specificity of dioxin toxicity and thus will aid attempts to predict the human and environmental risk that results from exposure to these pollutants. Second, the AHR is a prototype of a large super family of environmental sensors. What we learn here will shed significant light on a variety of environment-gene interactions. Third, it is likely that the AHR will be involved in a variety of human disorders. Detailed information about signaling can guide the pharmacology necessary to develop related therapeutics. Finally, identifying endogenous activators of the AHR will provide one of the most significant clues as to how and why this protein signals in development and begin to explain the conservation of this protein throughout evolution. In an effort to answer these questions, we propose the following specific aims:
Aim 1 : Identify/understand modifiers of AHR signaling through the use of genetic screens in the yeast, S cerevisiae. We will employ two screening approaches in yeast. First we will use a library of deletions to determine the role of each yeast gene product on AHR signal transduction. Second, we will expand upon these screens by using mammalian cDNAs to perform high copy modifier screens in yeast. Identified modifiers will then be characterized using both statistical clustering of their pharmacological action, as well as biochemical approaches to elucidate mechanism.
Aim 2 : Understand the mechanism of AHR modifiers through the use of signaling kinetics in mammalian cell culture. We propose to use fluorescently tagged molecules and reporters to elucidate the cellular mechanisms of AHR modifiers using a mammalian culture system. Once developed, this system will also serve as the basis for an activator screen described in Aim 3.
Aim 3 : Determine how the AHR signals during development. The phenotype of Ah null mice suggests the existence of a developmental activator of the AHR. To identify this factor, we propose to: 1) identify those developmental sites where the activator is most likely to be expressed; 2) screen for cDNAs encoding protein factors that activate the AHR using an activator trap protocol in cell culture; and 3) characterize the soluble factor derived from murine heart that activates the AHR in cell culture.
Aim 4 : Complete the high-resolution domain mapping studies of the AHR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
3R37ES005703-12S2
Application #
6619299
Study Section
Special Emphasis Panel (ZRG1 (03))
Program Officer
Heindel, Jerrold
Project Start
1991-08-01
Project End
2006-11-30
Budget Start
2002-02-01
Budget End
2002-11-30
Support Year
12
Fiscal Year
2002
Total Cost
$22,000
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Vaidyanathan, Bharat; Chaudhry, Ashutosh; Yewdell, William T et al. (2017) The aryl hydrocarbon receptor controls cell-fate decisions in B cells. J Exp Med 214:197-208
Pan, Xiaoyue; Bradfield, Christopher A; Hussain, M Mahmood (2016) Global and hepatocyte-specific ablation of Bmal1 induces hyperlipidaemia and enhances atherosclerosis. Nat Commun 7:13011
Perelis, Mark; Marcheva, Biliana; Ramsey, Kathryn Moynihan et al. (2015) Pancreatic ? cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. Science 350:aac4250
Johnson, Brian P; Walisser, Jacqueline A; Liu, Yan et al. (2014) Hepatocyte circadian clock controls acetaminophen bioactivation through NADPH-cytochrome P450 oxidoreductase. Proc Natl Acad Sci U S A 111:18757-62
Liu, Yan; Johnson, Brian P; Shen, Anna L et al. (2014) Loss of BMAL1 in ovarian steroidogenic cells results in implantation failure in female mice. Proc Natl Acad Sci U S A 111:14295-300
Mezrich, Joshua D; Nguyen, Linh P; Kennedy, Greg et al. (2012) SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation. PLoS One 7:e44547
Pauly, S Kyle; Fechner, John H; Zhang, Xiaoji et al. (2012) The Aryl Hydrocarbon Receptor Influences Transplant Outcomes in Response to Environmental Signals. Toxicol Environ Chem 94:1175-1187
Nukaya, Manabu; Walisser, Jacqueline A; Moran, Susan M et al. (2010) Aryl hydrocarbon receptor nuclear translocator in hepatocytes is required for aryl hydrocarbon receptor-mediated adaptive and toxic responses in liver. Toxicol Sci 118:554-63
Marcheva, Biliana; Ramsey, Kathryn Moynihan; Buhr, Ethan D et al. (2010) Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 466:627-31
Nukaya, Manabu; Lin, Bernice C; Glover, Edward et al. (2010) The aryl hydrocarbon receptor-interacting protein (AIP) is required for dioxin-induced hepatotoxicity but not for the induction of the Cyp1a1 and Cyp1a2 genes. J Biol Chem 285:35599-605

Showing the most recent 10 out of 23 publications